Full findings from lecanemab confirmatory phase III trial (CLARITY AD) will be presented at Alzheimer's Disease conference
Eisai Co., Ltd. will present the efficacy, safety and biomarker findings from the company’s Phase III confirmatory Clarity AD clinical trial for lecanemab development code: BAN2401), an investigational anti-amyloid beta (A beta) protofibril antibody for the potential treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference
Additionally, other important research from the lecanemab clinical development program and Eisai’s AD pipeline, including the company’s investigational anti-microtubule binding region (MTBR) tau antibody (E2814), will be presented in four oral and ten poster presentations.
Topline results from Clarity AD were announced in late September and showed that lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results, and the profile of Amyloid-Related Imaging Abnormalities (ARIA) incidence was within expectations.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins